ApoGen Raises $4M More in Series A to Combat Drug-Resistant Cancers, Adds Biotech Vets to Leadership

Biotech startup ApoGen raised an additional $4 million in its Series A round, totaling $11 million, to advance its development of treatments for drug-resistant cancers. The company also expanded its executive team by hiring Seattle biotech veteran Peter de Vries and added M Ventures' Investment Director Keno Gutierrez to its board.